血清肌酐与胱抑素C比值与肌少症的相关性

Correlation study of serum creatinine/cystatin C and sarcopenia

目的 探讨血清肌酐/胱抑素C(Scr/CysC)比值与肌少症的相关性,寻找肌少症特异的血清标记物.方法 病例对照研究,收集2020年11月至2022年2月在中南大学湘雅二医院老年医学科住院老年患者142例,其中诊断肌少症43例、非肌少症99例,分析Scr/CysC比值与肌少症的相关性.结果 肌少症组Scr/CysC比值71.5±12.5,明显低于非肌少症组81.9±15.8(t=3.823、P<0.001),Scr/CysC与肌肉质量、握力均呈正相关(r=0.52、0.69,均P<0.001).受试者工作特征曲线分析结果显示,在男性住院患者中,Scr/CysC比值在肌少症诊断中的曲线下面积为0.770(95%CI:0.655~0.886,P<0.001),诊断参考值为80.97,此时灵敏度为72.2%、特异度为68.4%;在女性住院患者中AUC为0.621(95%CI:0.474~0.768,P=0.099),诊断参考值为65.20,此时灵敏度为77.8%、特异度为58.3%.结论 血清Scr/CysC比值可能为老年男性肌少症患者的血清标志物,低于80.97时可能存在肌少症;在老年女性中,血清Scr/CysC比值对肌少症的诊断价值有待进一步研究.

Objective To explore the correlation between serum creatinine/cystatin C(Scr/CysC)ratio and sarcopenia,and search for serum markers specific to sarcopenia.Methods A retrospective case-control study of 142 hospitalized patients in the Department of Geriatrics,Xiangya Second Hospital,Central South University from November 2020 to February 2022 were collected,including 43 sarcopenia cases and 99 non sarcopenia cases.The correlation between Scr/CysC ratio and sarcopenia was analyzed and explored.Results The Scr/CysC ratio of 71.5±12.5 in the sarcopenia group was significantly lower than that of 81.9±15.8 in the non-sarcopenia group(t=3.823,P<0.001),and Scr/CysC was positively correlated with muscle mass and grip strength(r=0.52,0.69,both P<0.001).The results of the analysis of receiver operating characteristic curves of the subjects showed that in male inpatients,the area under the curve(AUC)of the Scr/CysC ratio in the diagnosis of sarcopenia was 0.770(95%CI:0.655 to 0.886,P<0.001),with a diagnostic reference value of 80.97,which gave a sensitivity of 72.2% and a specificity of 68.4%.In female inpatients the AUC was 0.621(95%CI:0.474 to 0.768,P=0.099),with a diagnostic reference value of 65.20,giving a sensitivity of 77.8% and a specificity of 58.3%.Conclusions The serum Scr/CysC ratio may be a serum marker for male sarcopenia patients,and sarcopenia may be considered when it is below 80.97;The diagnostic value in female sarcopenia needs further research.